Variable Viral blip (N= 15) No viral blip (N= 33) p OR 95% CI
Gender (N, %)
Female 2 (13.3 %) 7 (21.2%) 0.52 1 Reference
Male 13 (86.7%) 26 (78.8%) - 1.75 0.32-9.64
CD4+ T cell count per µL at T0 (N, %)
<500 per µL 2 (13.3%) 5 (15.2%) 0.87 1 Reference
>500 per µL 13 (86.7%) 28 (84.6%)) - 1.16 0.20-6.79
CD4+ T/CD8 ratio >=1 at T0 (N, %)
No 7 (46.7%) 18 (54.5%) 0.61 1 Reference
Yes 8 (53.5%) 15 (45.5%) - 1.37 0.40-4.66
CD4+ T/CD8 ratio >=0.4 at T0
No 1 (6.7%) 6 (18.2%) 0.32 1 Reference
Yes 14 (93.3%) 27 (81.8%) - 3.11 0.34-28.5
OIR at T0
No 10 (66.7%) 19 (57.6%) 0.56 1 Reference
Yes 5 (33.3%) 14 (42.4%) - 0.68 0.19-2.43
Positive anti-N T0
No 13 (86.7%) 28 (84.6%) 0.87 1 Reference
Yes 2 (13.3%) 5 (15.2%) - 0.87 0.15-5.04
Positive anti-N T3
No 14 (93.3) 28 (84.6%) 0.42 1 Reference
Yes 1 (6.7%) 5 (15.2%) - 0.4 0.04-3.76
Positive anti-N T6
No 13 (86.7%) 27 (81.8%) 0.68 1 Reference
Yes 2 (13.3%) 6 (18.2%) - 0.70 0.12-3.91
Positive anti-N T1c
No 12 (80%) 25 (75.8%) 0.75 1 Reference
Yes 3 (20%) 8 (24.2%) - 0.78 0.18-3.48
Anti-S titre T1b, U/mL
< 2,500 8 (53.3%) 13 (39.4%) 0.59 1 Reference
2,500 - 7,500 5 (33.3%) 13 (39.4%%) - 0.62 0.12-2.43
>7,500 - <12,500 1 (6.7%) 1 (3%) - 1.62 0.09-29.78
>12,500 1 (6.7%) 6 (18.2%) - 0.30 0.03-2.68
ND50 T1b
<1000 4 (26.7%) 12 (36.4%) 0.82 1 Reference
1000-2500 7 (46.7%) 8 (24.2) - 2.63 0.57-12
2500-5000 2 (13.3%) 5 (15.2%) - 1.2 0.16-8.8
>5000 2 (13.3%) 8 (24.2%) - 0.75 0.11-5.1
Blips before vaccination
No 9 (60%) 28 (84.6%) 0.06 1 Reference
Yes 6 (40%) 5 (15.2%) - 3.73 0.92-15.2